GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (STU:J75) » Definitions » Beneish M-Score

Kineta (STU:J75) Beneish M-Score : 0.08 (As of May. 29, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kineta Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.08 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Kineta's Beneish M-Score or its related term are showing as below:

STU:J75' s Beneish M-Score Range Over the Past 10 Years
Min: -2.18   Med: 1.5   Max: 3.52
Current: 0.08

During the past 4 years, the highest Beneish M-Score of Kineta was 3.52. The lowest was -2.18. And the median was 1.50.


Kineta Beneish M-Score Historical Data

The historical data trend for Kineta's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Beneish M-Score Chart

Kineta Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - 2.91

Kineta Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.52 -2.18 2.91 0.08

Competitive Comparison of Kineta's Beneish M-Score

For the Biotechnology subindustry, Kineta's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kineta's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Kineta's Beneish M-Score falls into.



Kineta Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Kineta for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 0+0.892 * 5.5981+0.115 * 1.8953
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.187+4.679 * -0.180071-0.327 * 3.5514
=-0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was €0.00 Mil.
Revenue was 0 + 0 + 0 + 4.764 = €4.76 Mil.
Gross Profit was 0 + 0 + 0 + 4.764 = €4.76 Mil.
Total Current Assets was €1.99 Mil.
Total Assets was €2.24 Mil.
Property, Plant and Equipment(Net PPE) was €0.25 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.01 Mil.
Selling, General, & Admin. Expense(SGA) was €10.98 Mil.
Total Current Liabilities was €7.84 Mil.
Long-Term Debt & Capital Lease Obligation was €0.14 Mil.
Net Income was -9.419 + -2.434 + -5.041 + 0.356 = €-16.54 Mil.
Non Operating Income was -3.541 + 1.429 + -1.222 + 1.27 = €-2.06 Mil.
Cash Flow from Operations was -3.69 + -3.737 + -0.215 + -6.429 = €-14.07 Mil.
Total Receivables was €0.00 Mil.
Revenue was 0.262 + -0.401 + 0.202 + 0.788 = €0.85 Mil.
Gross Profit was 0.262 + -0.401 + 0.202 + 0.788 = €0.85 Mil.
Total Current Assets was €8.94 Mil.
Total Assets was €12.19 Mil.
Property, Plant and Equipment(Net PPE) was €1.03 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.06 Mil.
Selling, General, & Admin. Expense(SGA) was €10.49 Mil.
Total Current Liabilities was €11.17 Mil.
Long-Term Debt & Capital Lease Obligation was €1.07 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 4.764) / (0 / 0.851)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.851 / 0.851) / (4.764 / 4.764)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1.987 + 0.251) / 2.238) / (1 - (8.937 + 1.033) / 12.189)
=0 / 0.182049
=0

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4.764 / 0.851
=5.5981

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.056 / (0.056 + 1.033)) / (0.007 / (0.007 + 0.251))
=0.051423 / 0.027132
=1.8953

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10.984 / 4.764) / (10.493 / 0.851)
=2.305626 / 12.3302
=0.187

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.138 + 7.844) / 2.238) / ((1.07 + 11.171) / 12.189)
=3.566577 / 1.004266
=3.5514

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-16.538 - -2.064 - -14.071) / 2.238
=-0.180071

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Kineta has a M-score of -0.22 signals that the company is likely to be a manipulator.


Kineta (STU:J75) Business Description

Traded in Other Exchanges
Address
219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Kineta (STU:J75) Headlines

No Headlines